Latest Bio-Gene Technology (ASX:BGT) News

A brutal split opened up in small caps: a few stocks surged on hard approvals and funding, while many resource names slid even after announcing big numbers. The week’s tape looked simple: investors paid for certainty and sold anything that still needs time, permits, or more cash.

Bio-Gene has signed a term sheet with Sumitomo Corporation and Nakashima Trading to introduce its 100% natural insecticide Qcide® to Japan’s $1 billion household pest market, aiming for a late 2026 launch.

One stock nearly doubled, another jumped more than 40%, and a finance heavyweight stayed elevated after a merger shock. In resources, the winners were mostly tied to “what was bought” or “what was funded”, while the laggards were often the ones where early optimism quickly turned into selling.

Bio-Gene Technology Limited reports strong progress in toxicology studies for Flavocide, targeting its first regulatory submission in Australia by March 2027. This milestone sets the stage for global registrations of the novel insecticide with a new mode of action.

Bio-Gene Technology Limited reports strong progress in advancing its Flavocide® and Qcide® insecticidal platforms, backed by US Department of Defense funding and key organic certification in the US.

Bio-Gene Technology reports promising progress on its US Department of Defense-funded insecticide projects, with early mosquito mortality evidence from its Flavocide wearable device and pending launch of its Qcide indoor spray program.

Bio-Gene Technology Limited has received a $519,500 R&D tax incentive from the Australian government, supporting its development of innovative bio-insecticides targeting insecticide resistance.

Bio-Gene Technology Limited updates on its development of two novel insecticides, Flavocide and Qcide, highlighting regulatory progress, commercial partnerships, and a strong market outlook across multiple sectors.

Bio-Gene Technology reports significant progress in developing its bio-insecticides Flavocide and Qcide, including new efficacy data and organic certification, positioning the company for growth amid rising global demand for safer pest control.

Bio-Gene Technology’s natural insecticide Qcide® has earned organic listing status from the US Organic Materials Review Institute, marking a pivotal step for its entry into the organic pest control market.

Bio-Gene Technology Limited reports significant progress in Q1 FY26, unveiling new product opportunities and positive efficacy data, alongside securing US Department of Defense grants.

Bio-Gene Technology Limited has addressed ASX concerns over the timing of its announcement on promising Flavocide efficacy data, confirming compliance with continuous disclosure rules after receiving final presentation materials from Purdue University.